



Administration of denosumab (Prolia) injections.

Version:	Owner:	Created:
1.1	Jodie Godfrey	June 2023
Published:	Approving Director:	Next Review
15/01/2025		15/01/2026

Contents

Indication

Denosumab (Prolia) is given to reduce the risk of osteoporotic fractures in post-menopausal women and men. Denosumab is an amber drug (3 months) and must be given in accordance with the BNSSG shared care guidance [accessed 27/09/2019]

<https://remedy.bnssgccg.nhs.uk/media/3288/denosumab-scp-2018.pdf>

Dose

The first injection will be given by the rheumatology department who will also do the baseline tests of checking renal function, calcium and vitamin D levels. They will instruct primary care regarding the subsequent doses. A prescription is to be done by the GP, or non-medical prescriber, and the injection to be stored in the practice fridge:

Denosumab 60mg as a sub-cutaneous injection into thigh, abdomen, or back of arm every 6 months (as pre-filled syringe)

The optimum duration of denosumab treatment is currently unknown. The shared care protocol advises that the risk benefit balance of continuing the treatment should normally be checked after 5 years (to include DEXA scan).

Administration

The injection comes as a pre-filled syringe and should be administered by a RGN.

A script will be added to the patients Emis notes and a printed FP10 will be signed by a GP. This will then be taken and collected from local pharmacy so that it is ready for the appointment.

Before administration, the solution should be inspected. Do not inject the solution if it contains particles, or is cloudy or discolored.

- Do not shake.
- To avoid discomfort at the site of injection, allow the pre-filled syringe to reach room temperature (up to 25°C) before injecting and inject slowly.
- Inject the entire contents of the pre-filled syringe.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Administration of denosumab (Prolia) injections 1.0

Osteonecrosis risk check the patient maintains adequate dental hygiene and has informed their dentist of denosumab therapy at each injection appointment.

Monitoring

Calcium levels should be checked prior to each dose of denosumab. This can be on the same day as the injection. **Annual Vitamin D & U&E&C (Vit D to be >50)**

Risk of hypocalcaemia post injection= check Calcium 2 weeks after as well (this recommendation from Nurse Specialist* 2017, not part of SCP currently.

Storage

- Store in a refrigerator 2°C – 8°C, do not freeze

Keep the pre-filled syringe in the outer carton in order to protect from light.

Prolia may be stored at room temperature (up to 25°C) for up to 30 days in the original container. Once removed from the refrigerator, Prolia must be used within this 30 day period.

Coding

1. In patient consultation add 'procedure' code 8BPW to add manufacturer/exp date/batch number & site (Nurse initials act as signature in EMIS)
2. Code 'informed consent' 892

Recalls

Diary recall: 'denosumab therapy' 6 month recall.

The person responsible for these recalls will liaise with the TRN to ensure the prescription is available and an appropriate appointment is booked

References

Prolia 60mg solution for injection in pre-filled syringe

<https://www.medicines.org.uk/emc/product/568/smpc> [accessed 27/09/2019]

***Nurse Specialist in Fracture Prevention and Bone Health- Cathy Churchman Tel: 0117 3421319 (Mon-thurs)**

Administration of denosumab (Prolia) injections 1.0

Version Control

Date	Version	Author	Change Details
01/06/2023	1	JG	New SOP.
13/11/2024	1.1	JG	Reviewed and uploaded onto new template